Mylan’s EpiPen Defense Against Generics Focuses On Device Design
This article was originally published in The Pink Sheet Daily
Executive Summary
Mylan wants Teva to conduct comparative studies of its epinephrine auto-injector and to resubmit its ANDA as a 505(b)(2) NDA; citizen petition includes declaration from former FDA advisory committee member.